Clinical Trial Update: Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating elsamitrucin (SPP 28090) in patients with relapsed or refractory Non-Hodgkin's Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Elsamitrucin (SPP-28090) (elsamitrucin)

Snippet

Sponsor: University of Southern California | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED